CD19-Targeted Lipid Nanoparticles for Delivering Venetoclax and BCL2 siRNA in B-Cell Acute Lymphoblastic Leukemia
نویسندگان
1 Department of Obstetrics and Gynaecology, Samarkand State Medical University, Samarkand, Uzbekistan
2 Faculty and Hospital Therapy, Occupational Diseases, Tashkent Medical Academy, Uzbekistan
3 Tashkent State Technical University, Uzbekistan
4 Department of Nuclear Medicine and Medical Radiology, Bukhara State Medical Institute Named After Abu Ali ibn Sino, Bukhara, Uzbekistan
5 Andijan State University, Uzbekistan
6 Department of Chemistry, Urgench State University, Urgench, Uzbekistan
7 Department of Infectious Diseases and Infectious Diseases of children, Bukhara State Medical Institute Named After Abu Ali ibn Sino, Bukhara, Uzbekistan
8 Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan
9 Medical Center for Dermatovenerology and Cosmetology, Ministry of Health of the Republic of Uzbekistan
10 Department of General Surgery, Fergana Medical Institute of Public Health, Uzbekistan
11 Department of Epidemiology and Infectious Disease Treatment, Nursing, Fergana Medical Institute of Public Health, Uzbekistan
12 Mamun University, Uzbekistan
13 Department of Industrial Technology of Medicines, Tashkent Pharmaceutical Institute, Tashkent, Uzbekistan
doi
10.22052/JNS.2025.02.019چکیده
B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive hematologic malignancy characterized by uncontrolled proliferation of immature B lymphocytes. Current therapeutic approaches, including chemotherapy and monoclonal antibodies, face challenges such as drug resistance and systemic toxicity. CD19-targeted lipid nanoparticles (LNPs) represent a promising strategy for precision medicine by enhancing drug delivery specificity and overcoming apoptotic resistance. Venetoclax, a potent BCL-2 inhibitor, and BCL2 siRNA, a gene-silencing agent, offer a synergistic approach to combat leukemic cell survival mechanisms. By co-delivering these therapeutic agents through LNPs, the targeted modulation of apoptotic pathways can improve treatment efficacy while minimizing off-target effects. This review explores the rationale, formulation, and clinical prospects of CD19-targeted lipid nanoparticles for co-delivery of Venetoclax and BCL2 siRNA in B-ALL therapy, highlighting their potential to revolutionize leukemia treatment.
